parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in tuft cells	0.75
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	1 Parkinson's trial, 0 stopped	1.00
literature PubMed	1 Parkinson's papers of 454	0.91
pathways Reactome	5 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 15790

VANGL2 in dopamine neurons, braak-0.38 (p 0.311) → -0.17 (p 0.663)receipt 15799
VANGL2 in astrocytes, braak-0.24 (p 0.539) → -0.11 (p 0.775)receipt 15798

receipt 15799: VANGL2 in dopamine neurons, braak

power: full sample -0.24 (p 0.332, n 18), 95% CI -0.64 to +0.25. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.24 (p 0.332, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.54 (p 0.021, n 18). not the mix.
skeptic: leave-one-out range -0.38 to -0.15, sign flips 0; without severely affected donors -0.24 (p 0.332, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for VANGL2 in dopamine neurons.

case closed: nothing better to follow up.

receipt 15798: VANGL2 in astrocytes, braak

power: full sample -0.13 (p 0.621, n 18), 95% CI -0.56 to +0.36. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.21 (p 0.393, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: -0.21 (p 0.413, n 18). could be the mix.
skeptic: leave-one-out range -0.29 to -0.02, sign flips 0; without severely affected donors -0.13 (p 0.621, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for VANGL2 in astrocytes.

case closed: nothing better to follow up.

loading the receipts